PDCD1 and non-small cell lung carcinoma: In an open-label clinical phase II study (MRTX-500) (29), sitravatinib in combination with nivolumab showed good clinical efficacy in patients with non-squamous NSCLC whose disease progressed on previous anti-PD-1/L1 regimen, with a primary endpoint objective response rate (ORR) of 18% (12/68), median progression-free-survival (mPFS) of 5.7 months, and median overall survival (mOS) of 14.9 months.